Clinical utility of inflammatory markers and advanced lipoprotein testing: Advice from an expert panel of lipid specialists
Tóm tắt
Từ khóa
Tài liệu tham khảo
1988, Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, Arch Intern Med, 148, 36, 10.1001/archinte.1988.00380010040006
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, 2002, Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report, Circulation, 106, 3143, 10.1161/circ.106.25.3143
Robinson, 2009, Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk, J Am Coll Cardiol, 53, 316, 10.1016/j.jacc.2008.10.024
Davidson, 2005, Results of the National Cholesterol Education Program (NCEP) evaluation project utilizing novel E-technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations, Am J Cardiol, 96, 556, 10.1016/j.amjcard.2005.04.019
Virani, 2011, Institutional, provider, and patient correlates of low-density lipoprotein and non-high-density lipoprotein cholesterol goal attainment according to the Adult Treatment Panel III guidelines, Am Heart J, 161, 1140, 10.1016/j.ahj.2011.03.023
Blaha, 2008, The importance of non-HDL cholesterol reporting in lipid management, J Clin Lipidol, 2, 267, 10.1016/j.jacl.2008.06.013
Drexel, 2010, Factors predicting cardiovascular events in statin-treated diabetic and non-diabetic patients with coronary atherosclerosis, Atherosclerosis, 208, 484, 10.1016/j.atherosclerosis.2009.08.026
Rosenson, 2010, Underappreciated opportunities for low-density lipoprotein management in patients with cardiometabolic residual risk, Atherosclerosis, 213, 1, 10.1016/j.atherosclerosis.2010.03.038
Ridker, 2008, JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein, N Engl J Med, 259, 2195, 10.1056/NEJMoa0807646
Blake, 2003, Potential cost-effectiveness of C-reactive protein screening followed by targeted statin therapy for the primary prevention of cardiovascular disease among patients without overt hyperlipidemia, Am J Med, 114, 485, 10.1016/S0002-9343(03)00074-3
Biasucci, 2010, Inflammatory markers, cholesterol and statins: pathophysiological role and clinical importance, Clin Chem Lab Med, 48, 1685, 10.1515/CCLM.2010.277
Pearson, 2003, Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association, Circulation, 107, 499, 10.1161/01.CIR.0000052939.59093.45
PLAC® Enzyme Immunoassay for the Quantitative Determination ofLp-PLA2 in Human Plasma and Serum product insert information (diaDexus, Inc. South San Francisco, CA). Available at http://www.framinghamheartstudy.org/share/protocols/lppla2m1_7s_protocol.pdf. Accessed May 16, 2011.
Contois, 2009, Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices, Clin Chem, 55, 407, 10.1373/clinchem.2008.118356
Mora, 2007, LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA), Atherosclerosis, 192, 211, 10.1016/j.atherosclerosis.2006.05.007
Otvos, 2011, Clinical implications of discordance between low-density lipoprotein cholesterol and particle numbers, J Clin Lipidol, 5, 105, 10.1016/j.jacl.2011.02.001
Nordestgaard, 2010, Lipoprotein (a) as a Cardiovascular Risk Factor, Eur Heart J, 31, 2844, 10.1093/eurheartj/ehq386
Ridker, 2003, Clinical application of C-reactive protein for cardiovascular disease detection and prevention, Circulation, 107, 363, 10.1161/01.CIR.0000053730.47739.3C
Ridker, 2003, C-reactive protein and risk of cardiovascular disease: evidence and clinical application, Curr Atheroscler Rep, 5, 341, 10.1007/s11883-003-0004-3
Ridker, 2000, C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women, N Engl J Med, 342, 836, 10.1056/NEJM200003233421202
Ridker, 1998, Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators, Circulation, 98, 839, 10.1161/01.CIR.98.9.839
Ridker, 1998, Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease, Circulation, 97, 425, 10.1161/01.CIR.97.5.425
Ridker, 1997, Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men, N Engl J Med, 336, 973, 10.1056/NEJM199704033361401
Kuller, 1996, Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial, Am J Epidemiol, 144, 537, 10.1093/oxfordjournals.aje.a008963
Tracy, 1997, Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project, Arterioscler Thromb Vasc Biol, 17, 1121, 10.1161/01.ATV.17.6.1121
Roivainen, 2000, Infections, inflammation, and the risk of coronary heart disease, Circulation, 101, 252, 10.1161/01.CIR.101.3.252
Harris, 1999, Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly, Am J Med, 106, 506, 10.1016/S0002-9343(99)00066-2
Mendall, 2000, C-reactive protein: relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men, Eur Heart J, 21, 1584, 10.1053/euhj.1999.1982
Kaptoge, 2010, C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis, Lancet, 375, 132, 10.1016/S0140-6736(09)61717-7
Liuzzo, 1994, The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina, N Engl J Med, 331, 417, 10.1056/NEJM199408183310701
Morrow, 1998, C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction, J Am Coll Cardiol, 31, 1460, 10.1016/S0735-1097(98)00136-3
Biasucci, 1999, Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability, Circulation, 99, 855, 10.1161/01.CIR.99.7.855
Toss, 1997, Fragmin during Instability in Coronary Artery Disease, Circulation, 96, 4204, 10.1161/01.CIR.96.12.4204
Lindahl, 2000, Fragmin during Instability in Coronary Artery Disease, N Engl J Med, 343, 1139, 10.1056/NEJM200010193431602
Sabatine, 2007, Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease, Circulation, 115, 1528, 10.1161/CIRCULATIONAHA.106.649939
Haverkate, 1997, Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group, Lancet, 349, 462, 10.1016/S0140-6736(96)07591-5
Ridker, 2004, Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores, Circulation, 109, 1955, 10.1161/01.CIR.0000125690.80303.A8
Chang, 2002, C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: Phosphorylcholine of oxidized phospholipids, Proc Natl Acad Sci U S A, 99, 13043, 10.1073/pnas.192399699
Shih, 2009, CRP is a novel ligand for the oxidized LDL receptor LOX-1, Am J Physiol Heart Circ Physiol, 296, H1643, 10.1152/ajpheart.00938.2008
Yasojima, 2001, Generation of C-reactive protein and complement components in atherosclerotic plaques, Am J Pathol, 158, 1039, 10.1016/S0002-9440(10)64051-5
Venugopal, 2002, Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells, Circulation, 106, 1439, 10.1161/01.CIR.0000033116.22237.F9
Verma, 2002, A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis, Circulation, 106, 913, 10.1161/01.CIR.0000029802.88087.5E
Fichtlscherer, 2000, Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease, Circulation, 102, 1000, 10.1161/01.CIR.102.9.1000
Devaraj, 2003, C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis, Circulation, 107, 398, 10.1161/01.CIR.0000052617.91920.FD
Verma, 2002, Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein, Circulation, 105, 1890, 10.1161/01.CIR.0000015126.83143.B4
Luscher, 2000, Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs, Circulation, 102, 2434, 10.1161/01.CIR.102.19.2434
Pasceri, 2001, Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs, Circulation, 103, 2531, 10.1161/01.CIR.103.21.2531
Bhakdi, 1999, Complement and atherogenesis: binding of CRP to degraded, nonoxidized LDL enhances complement activation, Arterioscler Thromb Vasc Biol, 19, 2348, 10.1161/01.ATV.19.10.2348
Torzewski, 1998, C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries, Arterioscler Thromb Vasc Biol, 18, 1386, 10.1161/01.ATV.18.9.1386
Zwaka, 2001, C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis, Circulation, 103, 1194, 10.1161/01.CIR.103.9.1194
Wang, 2003, C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle, Circulation, 107, 1783, 10.1161/01.CIR.0000061916.95736.E5
Ridker, 2008, Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein, N Engl J Med, 359, 2195, 10.1056/NEJMoa0807646
Koenig, 2011, Rosuvastatin for primary prevention in patients with European systematic coronary risk evaluation risk ≥ 5% or Framingham risk >20%: post hoc analyses of the JUPITER trial requested by European health authorities, Eur Heart J, 32, 75, 10.1093/eurheartj/ehq370
Yang, 2009, Clinical implications of JUPITER (Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) in a U.S. population insights from the ARIC (Atherosclerosis Risk in Communities) study, J Am Coll Cardiol, 54, 2388, 10.1016/j.jacc.2009.10.006
Ridker, 2001, Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events, N Engl J Med, 344, 1959, 10.1056/NEJM200106283442601
Ridker, 2008, C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men, Circulation, 118, 2243, 10.1161/CIRCULATIONAHA.108.814251
Ridker, 2007, Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score, JAMA, 297, 611, 10.1001/jama.297.6.611
Cushman, 1999, Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study, Circulation, 100, 17, 10.1161/01.CIR.100.7.717
Ridker, 2009, The JUPITER trial: results, controversies, and implications for prevention, Circ Cardiovasc Qual Outcomes, 2, 279, 10.1161/CIRCOUTCOMES.109.868299
Ridker, 2009, Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial, Lancet, 373, 1175, 10.1016/S0140-6736(09)60447-5
Ahmed, 2006, Acute coronary syndromes and diabetes: Is intensive lipid lowering beneficial? Results of the PROVE IT-TIMI 22 trial, Eur Heart J, 27, 2323, 10.1093/eurheartj/ehl220
Morrow, 2006, Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial, Circulation, 114, 281, 10.1161/CIRCULATIONAHA.106.628909
Nissen, 2004, Aggressive lipid-lowering therapy and regression of coronary atheroma—reply, JAMA, 292, 39
Nissen, 2005, Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease, N Engl J Med, 352, 29, 10.1056/NEJMoa042000
Mora, 2006, Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)—can C-reactive protein be used to target statin therapy in primary prevention?, Am J Cardiol, 97, 33A, 10.1016/j.amjcard.2005.11.014
Shen, 2009, Impact of genetic and environmental factors on hsCRP concentrations and response to therapeutic agents, Clin Chem, 55, 256, 10.1373/clinchem.2008.117754
Belalcazar, 2010, A 1-year lifestyle intervention for weight loss in individuals with type 2 diabetes reduces high C-reactive protein levels and identifies metabolic predictors of change: from the Look AHEAD (Action for Health in Diabetes) study, Diabetes Care, 33, 2297, 10.2337/dc10-0728
Horiuchi, 2010, Statin therapy reduces inflammatory markers in hypercholesterolemic patients with high baseline levels, J Atheroscler Thromb, 17, 722, 10.5551/jat.3632
Toth, 2010, Lipoprotein-associated phospholipase A2: role in atherosclerosis and utility as a cardiovascular biomarker, Exp Rev Cardiovasc Ther, 8, 425, 10.1586/erc.10.18
Braun, 2010, Lp-PLA2: a new target for statin therapy, Curr Atheroscler Rep, 12, 29, 10.1007/s11883-009-0074-y
Anderson, 2008, Lipoprotein-associated phospholipase A2: an independent predictor of coronary artery disease events in primary and secondary prevention, Am J Cardiol, 101, 23F, 10.1016/j.amjcard.2008.04.015
Ballantyne, 2004, Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study, Circulation, 109, 837, 10.1161/01.CIR.0000116763.91992.F1
Ballantyne, 2005, Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study, Arch Intern Med, 165, 2479, 10.1001/archinte.165.21.2479
Shahar, 2003, Plasma lipid profile and incident ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study, Stroke, 34, 623, 10.1161/01.STR.0000057812.51734.FF
Gorelick, 2008, Lipoprotein-associated phospholipase A2 and risk of stroke, Am J Cardiol, 101, 34F, 10.1016/j.amjcard.2008.04.017
Thompson, 2010, Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies, Lancet, 375, 1536, 10.1016/S0140-6736(10)60319-4
Koenig, 2006, Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress, Arterioscler Thromb Vasc Biol, 26, 1586, 10.1161/01.ATV.0000222983.73369.c8
Häkkinen, 1999, Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions, Arterioscler Thromb Vasc Biol, 19, 2909, 10.1161/01.ATV.19.12.2909
Anderson, 2008, Lipoprotein-associated phospholipase A2: an independent predictor of coronary artery disease events in primary and secondary prevention, Am J Cardiol, 101, 23F, 10.1016/j.amjcard.2008.04.015
Corson, 2008, Review of the evidence for the clinical utility of lipoprotein-associated A2 as a cardiovascular risk marker, Am J Cardiol, 101, 41F, 10.1016/j.amjcard.2008.04.018
Lerman, 2008, Lipoprotein-associated phospholipase A2: a risk marker or a risk factor?, Am J Cardiol, 101, 11F, 10.1016/j.amjcard.2008.04.014
Macphee, 1999, Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor, Biochem J, 338, 479, 10.1042/bj3380479
Lavi, 2007, Local production of lipoprotein-associated phospholipase A2 and lysophosphatidylcholine in the coronary circulation: association with early coronary atherosclerosis and endothelial dysfunction in humans, Circulation, 115, 2715, 10.1161/CIRCULATIONAHA.106.671420
Herrmann, 2009, Expression of lipoprotein-associated phospholipase A(2) in carotid artery plaques predicts long-term cardiac outcome, Eur Heart J, 30, 2930, 10.1093/eurheartj/ehp309
Wilensky, 2008, Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development, Nat Med, 14, 1059, 10.1038/nm.1870
Garcia-Garcia, 2009, Phospholipase A2 inhibitors, Curr Opin Lipidol, 20, 327, 10.1097/MOL.0b013e32832dd4c7
Davidson, 2008, Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines, Am J Cardiol, 101, 51F, 10.1016/j.amjcard.2008.04.019
2010, Lipoprotein-associated phospholipase A2 activity and mass in relation to vascular disease and nonvascular mortality, J Intern Med, 268, 348, 10.1111/j.1365-2796.2010.02258.x
Davidson, 2005, Clinical significance of statin pleiotropic effects: hypotheses versus evidence, Circulation, 111, 2280, 10.1161/01.CIR.0000167560.93138.E7
Schaefer, 2005, Effects of atorvastatin versus other statins on fasting and postprandial C-reactive protein and lipoprotein-associated phospholipase A2 in patients with coronary heart disease versus control subjects, Am J Cardiol, 95, 1025, 10.1016/j.amjcard.2005.01.023
Muhlestein, 2006, The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia. the DIACOR (Diabetes and Combined Lipid Therapy Regimen) Study, J Am Coll Cardiol, 48, 396, 10.1016/j.jacc.2006.05.009
Saougos, 2007, Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2, Arterioscler Thromb Vasc Biol, 27, 2236, 10.1161/ATVBAHA.107.147280
Tzotzas, 2008, Effects of a low-calorie diet associated with weight loss on lipoprotein-associated phospholipase A2 (Lp-PLA2) activity in healthy obese women, Nutr Metab Cardiovasc Dis, 18, 477, 10.1016/j.numecd.2007.04.004
Wilensky, 2008, Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development, Nat Med, 14, 1059, 10.1038/nm.1870
Serruys, 2008, Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque, Circulation, 118, 1172, 10.1161/CIRCULATIONAHA.108.771899
White, 2010, Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease, Am Heart J, 160, 655, 10.1016/j.ahj.2010.07.006
Ingelsson, 2007, Clinical utility of different lipid measures for prediction of coronary heart disease in men and women, JAMA, 298, 776, 10.1001/jama.298.7.776
Shai, 2004, Multivariate assessment of lipid parameters as predictors of coronary heart disease among postmenopausal women: potential implications for clinical guidelines, Circulation, 110, 2824, 10.1161/01.CIR.0000146339.57154.9B
Mora, 2009, Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women, Circulation, 119, 931, 10.1161/CIRCULATIONAHA.108.816181
Benn, 2007, Improving prediction of ischemic cardiovascular disease in the general population using apolipoprotein B: the Copenhagen City Heart Study, Arterioscler Thromb Vasc Biol, 27, 661, 10.1161/01.ATV.0000255580.73689.8e
Ridker, 2005, Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women, JAMA, 294, 326, 10.1001/jama.294.3.326
Jiang, 2004, Non-HDL cholesterol and apolipoprotein B predict cardiovascular disease events among men with type 2 diabetes, Diabetes Care, 27, 1991, 10.2337/diacare.27.8.1991
Pischon, 2005, Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men, Circulation, 112, 3375, 10.1161/CIRCULATIONAHA.104.532499
Bruno, 2006, Effect of age on the association of non-high-density-lipoprotein cholesterol and apolipoprotein B with cardiovascular mortality in a Mediterranean population with type 2 diabetes: the Casale Monferrato study, Diabetologia, 49, 937, 10.1007/s00125-006-0195-6
Chien, 2007, Apolipoprotein B and non-high density lipoprotein cholesterol and the risk of coronary heart disease in Chinese, J Lipid Res, 48, 2499, 10.1194/jlr.M700213-JLR200
Holme, 2008, Relationships between lipoprotein components and risk of myocardial infarction: age, gender and short versus longer follow-up periods in the Apolipoprotein MOrtalityRISk study (AMORIS), J Intern Med, 264, 30, 10.1111/j.1365-2796.2008.01925.x
McQueen, 2008, Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study, Lancet, 372, 224, 10.1016/S0140-6736(08)61076-4
Parish, 2009, The joint effects of apolipoprotein B, apolipoprotein A1, LDL cholesterol, and HDL cholesterol on risk: 3510 cases of acute myocardial infarction and 9805 controls, Eur Heart J, 30, 2137, 10.1093/eurheartj/ehp221
Talmud, 2002, Nonfasting apolipoprotein B and triglyceride levels as a useful predictor of coronary heart disease risk in middle-aged UK men, Arterioscler Thromb Vasc Biol, 22, 1918, 10.1161/01.ATV.0000035521.22199.C7
Sniderman, 2009, ApoB and the atherogenic ApoB dyslipoproteinemias, 196
Blom, 2005, Screening for dysbetalipoproteinemia by plasma cholesterol and apolipoprotein B concentrations, Clin Chem, 51, 904, 10.1373/clinchem.2004.047001
Sniderman, 2007, Diagnosis of type III hyperlipoproteinemia from plasma total cholesterol, triglyceride, and apolipoprotein B, J Clin Lipidol, 1, 256, 10.1016/j.jacl.2007.07.006
Krauss, 1982, Identification of multiple subclasses of plasma low density lipoproteins in normal humans, J Lipid Res, 23, 97, 10.1016/S0022-2275(20)38178-5
Sniderman, 2001, Hypertriglyceridemic hyperapob: the unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus, Ann Intern Med, 135, 447, 10.7326/0003-4819-135-6-200109180-00014
Lamarche, 1999, The small, dense LDL phenotype and the risk of coronary heart disease: epidemiology, patho-physiology and therapeutic aspects, Diabetes Metab, 25, 199
Krauss, 2004, Metabolic abnormalities: triglyceride and low-density lipoprotein, Endocrinol Metab Clin North Am, 33, 405, 10.1016/j.ecl.2004.03.016
Genest, 1993, Familial hypoalphalipoproteinemia in premature coronary artery disease, Arterioscler Thromb, 13, 1728, 10.1161/01.ATV.13.12.1728
Sniderman, 2001, High apolipoprotein B with low high-density lipoprotein cholesterol and normal plasma triglycerides and cholesterol, Am J Cardiol, 87, 792, 10.1016/S0002-9149(00)01508-3
Sniderman, 2002, A proposal to redefine familial combined hyperlipidaemia - third workshop on FCHL held in Barcelona from 3 to 5 May 2001, during scientific sessions of the European Society for Clinical Investigation, Eur J Clin Invest, 71, 10.1046/j.1365-2362.2002.00941.x
Veerkamp, 2004, Nomogram to diagnose familial combined hyperlipidemia on the basis of results of a 5-year follow-up study, Circulation, 109, 2980, 10.1161/01.CIR.0000130646.93255.86
Sniderman, 2010, Diagnosis and treatment of apolipoprotein B dyslipoproteinemias, Nat Rev Endocrinol, 6, 335, 10.1038/nrendo.2010.50
Liu, 2006, Non-high-density lipoprotein and very-low-density lipoprotein cholesterol and their risk predictive values in coronary heart disease, Am J Cardiol, 98, 1363, 10.1016/j.amjcard.2006.06.032
Di Angelantonio, 2009, Major lipids, apolipoproteins, and risk of vascular disease, JAMA, 302, 1993, 10.1001/jama.2009.1619
Sniderman, 2011, A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk, Circ Cardiovasc Qual Outcomes, 4, 337, 10.1161/CIRCOUTCOMES.110.959247
Contois, 2009, Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices, Clin Chem, 55, 407, 10.1373/clinchem.2008.118356
Contois, 2011, Reliability of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol and apolipoprotein B measurement, J Clin Lipidol, 5, 264, 10.1016/j.jacl.2011.05.004
Marcovina, 1994, International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. IV. Comparability of apolipoprotein B values by use of International Reference Material, Clin Chem, 40, 586, 10.1093/clinchem/40.4.586
Elovson, 1988, Plasma very low density lipoproteins contain a single molecule of apolipoprotein B, J Lipid Res, 29, 1461, 10.1016/S0022-2275(20)38425-X
Kane, 1983, Apolipoprotein B: structural and metabolic heterogeneity, Annu Rev Physiol, 45, 637, 10.1146/annurev.ph.45.030183.003225
Langsted, 2011, Nonfasting lipids, lipoproteins, and apolipoproteins in individuals with and without diabetes: 58,434 individuals from the Copenhagen General Population Study, Clin Chem, 57, 482, 10.1373/clinchem.2010.157164
Smith, 1982, Intimal and medial plasma protein concentrations and endothelial function, Atherosclerosis, 41, 295, 10.1016/0021-9150(82)90194-0
Miller, 2010, Seven direct methods for measuring HDL and LDL cholesterol compared with ultracentrifugation reference measurement procedures, Clin Chem, 56, 977, 10.1373/clinchem.2009.142810
Genest, 2009, 2009 Canadian Cardiovascular Society/Canadian Guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult—2009 recommendations, Can J Cardiol, 25, 567, 10.1016/S0828-282X(09)70715-9
Grundy, 2004, Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines, J Am Coll Cardiol, 44, 720, 10.1016/j.jacc.2004.07.001
Wiesbauer, 2009, Familial-combined hyperlipidaemia in very young myocardial infarction survivors (<or =40 years of age), Eur Heart J, 30, 1073, 10.1093/eurheartj/ehp051
Hayward, 2006, Narrative review: lack of evidence for recommended low-density lipoprotein treatment targets: a solvable problem, Ann Intern Med, 145, 520, 10.7326/0003-4819-145-7-200610030-00010
Gotto, 2000, Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS), Circulation, 101, 477, 10.1161/01.CIR.101.5.477
Colhoun, 2004, Primary preventions of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial, Lancet, 364, 685, 10.1016/S0140-6736(04)16895-5
LaRosa, 2005, intensive lipid lowering with atorvastatin in patients with stable coronary disease, N Engl J Med, 352, 1425, 10.1056/NEJMoa050461
Ridker, 2008, Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein, N Engl J Med, 359, 2195, 10.1056/NEJMoa0807646
2002, MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial, Lancet, 360, 7, 10.1016/S0140-6736(02)09327-3
Ray, 2009, Prognostic utility of Apo B/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT TIMI 22, Arterioscler Thromb Vasc Biol, 29, 424, 10.1161/ATVBAHA.108.181735
Roeters van Lennep, 2000, Apolipoprotein concentrations during treatment and recurrent coronary artery disease events, Arterioscler Thromb Vasc Biol, 20, 2408, 10.1161/01.ATV.20.11.2408
Kastelein, 2008, Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment, Circulation, 117, 3002, 10.1161/CIRCULATIONAHA.107.713438
Simes, 2002, Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels?, Circulation, 105, 1162, 10.1161/hc1002.105136
Shepherd, 2002, Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial, Lancet, 360, 1623, 10.1016/S0140-6736(02)11600-X
Sniderman, 2008, Differential response of cholesterol particle measures of atherogenic lipoproteins to LDL-lowering therapy: implications for clinical practice, J Clin Lipidol, 2, 36, 10.1016/j.jacl.2007.12.006
Stein, 2005, Assessment of reaching goal in patients with combined hyperlipidemia: low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, or apolipoprotein B, Am J Cardiol, 96, 36K, 10.1016/j.amjcard.2005.08.006
Brunzell, 2008, American College of Cardiology Foundation. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation, Diabetes Care, 31, 811, 10.2337/dc08-9018
Grundy, 2002, Low-density lipoprotein, non-high density lipoprotein and apolipoprotein B as targets of lipid-lowering therapy, Circulation, 106, 2526, 10.1161/01.CIR.0000038419.53000.D6
The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group, 1998, Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels, N Engl J Med, 339, 1349, 10.1056/NEJM199811053391902
Downs, 1998, Primary prevention of acute coronary events with Lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS, JAMA, 279, 1615, 10.1001/jama.279.20.1615
Pedersen, 2005, High-dose atorvastatin vs usual dose simvastatin for secondary prevention after myocardial infarction. The IDEAL Study: a randomized controlled trial, JAMA, 294, 2437, 10.1001/jama.294.19.2437
Cannon, 2004, Intensive versus moderate lipid lowering with statins after acute coronary syndromes, N Engl J Med, 350, 1495, 10.1056/NEJMoa040583
Jacobson, 2011, Opening a new lipid “apo−thecary”: incorporating apolipoproteins as potential risk factors and treatment targets to reduce cardiovascular risk, Mayo Clin Proc, 86, 762, 10.4065/mcp.2011.0128
Robinson, 2005, Pleiotropic effects of statins: benefit beyond cholesterol reduction?, J Am Coll Cardiol, 46, 1855, 10.1016/j.jacc.2005.05.085
Robinson, 2009, Meta-analysis of the relationship between non-high-density cholesterol reduction and coronary heart disease risk, J Am Coll Cardiol, 53, 316, 10.1016/j.jacc.2008.10.024
Ramjee, 2011, Non-HDL versus Apo B in cardiovascularrisk stratification: do the math, J Am Coll Cardiol, 58, 457, 10.1016/j.jacc.2011.05.009
Virani, 2011, Institutional, provider, and patient correlates of low-density lipoprotein and non-high-density lipoprotein cholesterol goal attainment according to the Adult Treatment Panel III guidelines, Am Heart J, 161, 1140, 10.1016/j.ahj.2011.03.023
Otvos, 2002, Measurement issues related to lipoprotein heterogeneity, Am J Cardiol, 90, 22i, 10.1016/S0002-9149(02)02632-2
Cromwell, 2004, Low-density lipoprotein particle number and risk for cardiovascular disease, Curr Atheroscler Rep, 6, 381, 10.1007/s11883-004-0050-5
Cromwell, 2007, LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study—Implications for LDL management, J Clin Lipidol, 1, 583, 10.1016/j.jacl.2007.10.001
Sniderman, 2003, Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment, Lancet, 361, 777, 10.1016/S0140-6736(03)12663-3
Sniderman, 2008, Differential response of cholesterol and particle measures of atherogenic lipoproteins to LDL-lowering therapy: implications for clinical practice, J Clin Lipidol, 2, 36, 10.1016/j.jacl.2007.12.006
Cromwell, 2009, Low-density lipoprotein and apolipoprotein B: clinical use in patients with coronary heart disease, Curr Cardiol Rep, 11, 468, 10.1007/s11886-009-0067-z
Kathiresan, 2006, Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study, Circulation, 113, 20, 10.1161/CIRCULATIONAHA.105.567107
Cromwell, 2006, Heterogeneity of low-density lipoprotein particle number in patients with type 2 diabetes mellitus and low-density lipoprotein cholesterol <100 mg/dL, Am J Cardiol, 98, 1599, 10.1016/j.amjcard.2006.07.036
Otvos, 2011, Clinical implications of discordance between low-density lipoprotein cholesterol and particle number, J Clin Lipidol, 5, 105, 10.1016/j.jacl.2011.02.001
Otvos, 2003, LDL particles, but not LDL cholesterol, are highly elevated in the metabolic syndrome—Results from the Framingham Offspring Study, Circulation, 108
Garvey, 2003, Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance, Diabetes, 52, 453, 10.2337/diabetes.52.2.453
Glasziou, 2008, When should a new test become the current reference standard?, Ann Intern Med, 149, 816, 10.7326/0003-4819-149-11-200812020-00009
Greenland, 2010, 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, J Am Coll Cardiol, 56, e50, 10.1016/j.jacc.2010.09.001
Nielsen, 1996, Transfer of low density lipoprotein into the arterial wall and risk of atherosclerosis, Atherosclerosis, 123, 1, 10.1016/0021-9150(96)05802-9
Rudd, 2002, Atherosclerotic biology and epidemiology of disease, 2
Nordestgaard, 1995, Selective retention of VLDL, IDL, and LDL in the arterial intima of genetically hyperlipidemic rabbits in vivo. Molecular size as a determinant of fractional loss from the intima-inner media, Arterioscler Thromb Vasc Biol, 15, 534, 10.1161/01.ATV.15.4.534
Tabas, 2007, Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications, Circulation, 116, 1832, 10.1161/CIRCULATIONAHA.106.676890
Sniderman, 2002, A proposal to redefine familial combined hyperlipidaemia—third workshop on FCHL held in Barcelona from 3 to 5 May 2001, during the scientific sessions of the European Society for Clinical Investigation, Eur J Clin Invest, 32, 71, 10.1046/j.1365-2362.2002.00941.x
Gaddi, 2007, Practical guidelines for familial combined hyperlipidemia diagnosis: an up-date, Vasc Health Risk Manag, 3, 877
Rosenson, 2002, Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial, Am J Cardiol, 90, 89, 10.1016/S0002-9149(02)02427-X
Otvos, 2006, Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial, Circulation, 113, 1556, 10.1161/CIRCULATIONAHA.105.565135
Contois, 2009, Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices, Clin Chem, 55, 407, 10.1373/clinchem.2008.118356
Cromwell, 2007, Lipoprotein subfraction analysis using nuclear magnetic resonance spectroscopy, 217
Erqou, 2009, Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality, JAMA, 302, 412, 10.1001/jama.2009.1063
Danesh, 2000, Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies, Circulation, 102, 1082, 10.1161/01.CIR.102.10.1082
Bennet, 2008, Lipoprotein(a) levels and risk of future coronary heart disease: large-scale prospective data, Arch Intern Med, 168, 598, 10.1001/archinte.168.6.598
Nordestgaard, 2010, Lipoprotein (a) as a cardiovascular risk factor, Eur Heart J, 31, 2844, 10.1093/eurheartj/ehq386
Kamstrup, 2009, Geneticallyelevated lipoprotein(a) and increased risk of myocardial infarction, JAMA, 301, 2331, 10.1001/jama.2009.801
Rader, 1994, The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate, J Clin Invest, 93, 2758, 10.1172/JCI117292
Koschinsky, 2004, Structure-function relationships in apolipoprotein(a): insights into lipoprotein(a) assembly and pathogenicity, Curr Opin Lipidol, 15, 167, 10.1097/00041433-200404000-00009
Kronenberg, 1999, Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: prospective results from the Bruneck study, Circulation, 100, 1154, 10.1161/01.CIR.100.11.1154
Sotiriou, 2006, Lipoprotein(a) in atherosclerotic plaques recruits inflammatory cells through interaction with Mac-1 integrin, FASEB J, 20, 559, 10.1096/fj.05-4857fje
Kiechl, 2007, Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: Prospective results from the Bruneck study, Arterioscler Thromb Vasc Biol, 27, 1788, 10.1161/ATVBAHA.107.145805
Bergmark, 2008, A novel function of lipoprotein (a) as a preferential carrier of oxidized phospholipids in human plasma, J Lipid Res, 49, 2230, 10.1194/jlr.M800174-JLR200
Tsimikas, 2010, Oxidation-specific biomarkers, lipoprotein(a), and risk of fatal and nonfatal coronary events, J Am Coll Cardiol, 56, 946, 10.1016/j.jacc.2010.04.048
Rouy, 1991, Lipoprotein(a) impairs generation of plasmin by fibrin-bound tissue-type plasminogen activator. In vitro studies in a plasma milieu, Arterioscler Thromb, 11, 629, 10.1161/01.ATV.11.3.629
Boonmark, 1997, Modification of apolipoprotein(a) lysine binding site reduces atherosclerosis in transgenic mice, J Clin Invest, 100, 558, 10.1172/JCI119565
Utermann, 2001, Lipoprotein(a), 2753
Smith, 2004, Mendelian randomization: prospects, potentials, and limitations, Int J Epidemiol, 33, 30, 10.1093/ije/dyh132
Koschinsky, 2009, Lipoprotein(a), 130
Suk Danik, 2008, Rifai N, Buring JE, Ridker PM. Lipoprotein(a), hormone replacement therapy, and risk of future cardiovascular events, J Am Coll Cardiol, 52, 124, 10.1016/j.jacc.2008.04.009
Tziomalos, 2009, Lipoprotein a: where are we now?, Curr Opin Cardiol, 24, 351, 10.1097/HCO.0b013e32832ac21a
Sacks, 2003, Clinical review 163: Cardiovascular endocrinology: Low-density lipoprotein size and cardiovascular disease: a reappraisal, J Clin Endocrinol Metab, 88, 4525, 10.1210/jc.2003-030636
Superko, 2009, Advanced lipoprotein testing and subfractionation are clinically useful, Circulation, 119, 2383, 10.1161/CIRCULATIONAHA.108.809582
Ip, 2009, Systematic review: association of low-density lipoprotein subfractions with cardiovascular outcomes, Ann Intern Med, 150, 474, 10.7326/0003-4819-150-7-200904070-00007
Ensign, 2006, Disparate LDL phenotypic classification among 4 different methods assessing LDL particle characteristics, Clin Chem, 52, 1722, 10.1373/clinchem.2005.059949
Chung, 2009, Comparability of methods for LDL subfraction determination: a systematic review, Atherosclerosis, 205, 342, 10.1016/j.atherosclerosis.2008.12.011
Rudel, 1986, Low density lipoproteins in atherosclerosis, J Lipid Res, 27, 465, 10.1016/S0022-2275(20)35191-9
Patsch, 1982, Characterization of lipoprotein in a kindred with familial hypercholesterolemia, J Lipid Res, 23, 1196, 10.1016/S0022-2275(20)38058-5
Mora, 2007, LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA), Atherosclerosis, 192, 211, 10.1016/j.atherosclerosis.2006.05.007
Campos, 1995, Predominance of large LDL and reduced HDL2 cholesterol in normolipidemic men with coronary artery disease, Arterioscler Thromb Vasc Biol, 15, 1043, 10.1161/01.ATV.15.8.1043
Campos, 2001, Low-density lipoprotein size, pravastatin treatment, and coronary events, JAMA, 286, 1468, 10.1001/jama.286.12.1468
Lamarche, 1995, Prevalence of dyslipidemic phenotypes in ischemic heart disease (prospective results from the Québec Cardiovascular Study), Am J Cardiol, 75, 1189, 10.1016/S0002-9149(99)80760-7
Otvos, 2006, Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial, Circulation, 113, 1556, 10.1161/CIRCULATIONAHA.105.565135
Kuller, 2002, Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the cardiovascular health study, Arterioscler Thromb Vasc Biol, 22, 1175, 10.1161/01.ATV.0000022015.97341.3A
Blake, 2002, Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women, Circulation, 106, 1930, 10.1161/01.CIR.0000033222.75187.B9
Hallman, 2004, Relationship between low-density lipoprotein subclasses and asymptomatic atherosclerosis in subjects from the Atherosclerosis Risk in Communities (ARIC) Study, Biomarkers, 9, 190, 10.1080/13547500410001720758
Ross, 1999, Atherosclerosis—an inflammatory disease, N Engl J Med, 340, 115, 10.1056/NEJM199901143400207
Williams, 1990, Changes in lipoprotein subfractions during diet-induced and exercise-induced weight loss in moderately overweight men, Circulation, 81, 1293, 10.1161/01.CIR.81.4.1293
Vakkilainen, 2003, Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease. The Diabetes Atherosclerosis Intervention Study (DAIS), Circulation, 107, 1733, 10.1161/01.CIR.0000057982.50167.6E
Rosenson, 2011, HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events, Clin Chem, 57, 392, 10.1373/clinchem.2010.155333
Reilly, 2007, HDL proteomics: pot of gold or Pandora’s box?, J Clin Invest, 117, 595, 10.1172/JCI31608
Di Angelantonio, 2009, Major lipids, apolipoproteins and risk of vascular disease, JAMA, 302, 1993, 10.1001/jama.2009.1619
Baigent, 2005, Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins, Lancet, 366, 1267, 10.1016/S0140-6736(05)67394-1
Barter, 2007, HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events, N Engl J Med, 357, 1301, 10.1056/NEJMoa064278
Ridker, 2010, HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial, Lancet, 376, 333, 10.1016/S0140-6736(10)60713-1
Briel, 2009, Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis, BMJ, 338, b92, 10.1136/bmj.b92
Otvos, 2006, Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial, Circulation, 113, 1556, 10.1161/CIRCULATIONAHA.105.565135
Williams, 2011, Prospective study of coronary heart disease vs. HDL2, HDL3, and other lipoproteins in Gofman’s Livermore Cohort, Atherosclerosis, 214, 196, 10.1016/j.atherosclerosis.2010.10.024
Asztalos, 2006, LpA-I, LpA-I: A-II HDL and CHD-risk: The Framingham Offspring Study and the Veterans Affairs HDL Intervention Trial, Atherosclerosis, 188, 59, 10.1016/j.atherosclerosis.2005.10.018